Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of a new multivalent pneumococcal vaccine called PG4 in healthy infants. This vaccine is being compared to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC. The study aims to see how well the new vaccine helps fight germs that cause pneumonia, meningitis, and ear infections, and whether it provides additional protection against pneumococcal disease compared to the existing vaccine. The study includes three groups of infants based on age and location. Group 1 involves about 3000 infants who are 2 months old and will receive either PG4 or 20vPnC shots into the left thigh muscle at 2, 4, 6, and 12 to 15 months of age. Groups 2 and 3, with smaller numbers of infants from outside the United States aged 2 to 6 months, will receive different schedules of PG4 or 20vPnC either intramuscularly or under the skin. Each infant will be randomly assigned to one of the vaccine types and administration methods. Participants will be involved in the study for about 12 to 19 months depending on their group. During this time, infants will attend six clinic visits and one phone call, where parents or guardians will be asked about any side effects experienced. Blood samples will be collected three times to measure the immune response through proteins that fight the pneumococcal disease germs. The study also monitors local and systemic reactions, adverse events, and serious adverse events following vaccination.
Actively Recruiting
This research aims to study pediatric participants under 12 years old with influenza to evaluate the prevalence of specific amino acid changes that might affect the viruss susceptibility to baloxavir marboxil. The study includes two parts Part A focuses on surveillance of resistance-associated substitutions before and after treatment, while Part B examines the transmission of influenza from treated children to their household contacts. Enrollment for Part B has stopped as per the latest protocol version. Participants in Part A receive a single oral dose of baloxavir marboxil on the first day, with the dose based on their body weight and age. Household contacts of these participants may be enrolled in Part B but do not receive treatment. The study monitors viral changes and resistance by collecting samples on days 1, 4, 6, and 10, with further assessments up to day 29. The study is open-label and conducted across multiple centers. During the study, participants will be assessed for resistance-associated virus mutations and changes in viral load using laboratory tests including RT-PCR. Household contacts are monitored for influenza transmission and symptoms. Safety is tracked by reporting adverse events during the follow-up period. This trial is expected to continue until mid-2027, with participants involved for up to 29 days after dosing for primary evaluations and extended monitoring of virus resistance and transmission.